TTR and amyloidosis: The benefits of lowering mutant TTR levels in patients with hATTR amyloidosis have been demonstrated by OLT [40, 41], and data from other amyloidoses show that clinical outcomes can be improved by reducing amyloidogenic protein [42–44].